Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Sullivan

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Journal of Cancer|October 25, 2013
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJoel G Turner, Jana Dawson, Michael F Emmons, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2005
The absolute bioavailability of oral vinorelbine in patients with solid tumorsRichard M Lush, Jeannine S McCune, Leticia Tetteh, et al.
Melanoma Research|May 13, 2009
Src activation in melanoma and Src inhibitors as therapeutic agents in melanomaJade Homsi, Christopher L Cubitt, Shumin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeLesley Seymour, Susan Groshen, Gary L Rosner, et al.
Reviews on Recent Clinical Trials|January 28, 2015
Building a long distance training program to enhance clinical cancer research capacity in Puerto RicoCaroline B Appleyard, Scott J Antonia, Daniel M Sullivan, et al.
Molecular Cancer Therapeutics|May 3, 2015
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic CancerSabiha Kazim, Mokenge P Malafa, Domenico Coppola, et al.
Scientific Reports|November 26, 2015
Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaDiana Yu, Elliot Kahen, Christopher L Cubitt, et al.
British Journal of Haematology|December 15, 2018
Lenalidomide-based response-adapted therapy for older adults without high risk myelomaRachid Baz, Syeda Mahrukh Hussnain Naqvi, Jae-Hoon Lee, et al.
Blood|August 19, 2006
ABCG2 expression, function, and promoter methylation in human multiple myelomaJoel G Turner, Jana L Gump, Chunchun Zhang, et al.
Journal of Hematology & Oncology|August 26, 2016
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G Turner, Jana L Dawson, Steven Grant, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Journal of Cancer|October 25, 2013
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJoel G Turner, Jana Dawson, Michael F Emmons, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2005
The absolute bioavailability of oral vinorelbine in patients with solid tumorsRichard M Lush, Jeannine S McCune, Leticia Tetteh, et al.
Melanoma Research|May 13, 2009
Src activation in melanoma and Src inhibitors as therapeutic agents in melanomaJade Homsi, Christopher L Cubitt, Shumin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeLesley Seymour, Susan Groshen, Gary L Rosner, et al.
Reviews on Recent Clinical Trials|January 28, 2015
Building a long distance training program to enhance clinical cancer research capacity in Puerto RicoCaroline B Appleyard, Scott J Antonia, Daniel M Sullivan, et al.
Molecular Cancer Therapeutics|May 3, 2015
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic CancerSabiha Kazim, Mokenge P Malafa, Domenico Coppola, et al.
Scientific Reports|November 26, 2015
Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaDiana Yu, Elliot Kahen, Christopher L Cubitt, et al.
British Journal of Haematology|December 15, 2018
Lenalidomide-based response-adapted therapy for older adults without high risk myelomaRachid Baz, Syeda Mahrukh Hussnain Naqvi, Jae-Hoon Lee, et al.
Blood|August 19, 2006
ABCG2 expression, function, and promoter methylation in human multiple myelomaJoel G Turner, Jana L Gump, Chunchun Zhang, et al.
Journal of Hematology & Oncology|August 26, 2016
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJoel G Turner, Jana L Dawson, Steven Grant, et al.
Pageof 9